* Muscles, Bones, Joints, and Disorders

* Arthritis, Gout, Lupus, Fibromyalgia

* Find Rheumatologists by State

* News, Info, Resources

Filter= Infliximab


  Exact Time




Custom Search



     Like us:     Follow us:  



* Go To Z101.COM *






* Internet Search Results 

  *** Search Filter: "Infliximab"


Infliximab - Wikipedia
Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha and is used to treat autoimmune diseases.Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.

Infliximab Injection - Drugs.com
Warning Very bad and sometimes deadly infections have happened in patients who take infliximab injection. Most people who had these infections were taking other drugs to lower the immune system like methotrexate or steroid drugs.

infliximab, Remicade Side Effects & Dosing - MedicineNet
Infliximab is administered intravenously. The recommended dose is a 5 mg/kg infusion at 0, 2, and 6 weeks and then 5 mg/kg every 8 weeks for moderate to severe active Crohn's disease or fistulizing Crohn's disease in adult or pediatric patients.

Official Website for REMICADE® (infliximab)
Learn about treatment with REMICADE® (infliximab) across all uses and see Important Safety Information and Medication Guide for discussion with your doctor.

Remicade, Inflectra (infliximab) dosing, indications ...
Medscape - Rheumatoid arthritis, inflammatory bowel-specific dosing for Remicade, Inflectra (infliximab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Infliximab | definition of infliximab by Medical dictionary
infliximab [in-flik´sĭ-mab] an antibody against tumor necrosis factor, used in treatment of crohn's disease and rheumatoid arthritis. infliximab Remicade Pharmacologic class: Monoclonal antibody Therapeutic class: Antirheumatic, GI anti-inflammatory Pregnancy risk category B FDA Box Warning • Patients treated with infliximab are at increased risk ...

Remicade (Infliximab) - Side Effects, Dosage, Interactions ...
Remicade is the brand name for infliximab, an injectable prescription drug that's used to treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (a type of spinal ...

Infliximab Intravenous : Uses, Side Effects, Interactions ...
Find patient medical information for Infliximab Intravenous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Infliximab Medical Definition | Merriam-Webster Medical ...
Medical definition of infliximab: an immunosuppressive drug administered by intravenous injection especially to treat the symptoms of Crohn's disease, ulcerative colitis, and rheumatoid arthritis.

Biosimilar | Official Website for REMICADE® (infliximab)
Even though infliximab biosimilars are very similar to REMICADE ®, that doesn’t mean they are interchangeable with REMICADE ®. Biosimilarity Interchangeability . According to the FDA, no infliximab biosimilar has been proven to be interchangeable with REMICADE®



* Live EBAY Auctions

Remicade Infliximab Pharmaceutical Drug Rep Pharma Promo Clipboard Sealed
End Date: Saturday May-25-2019 5:29:16 PDT
Buy It Now for only: $24.99
Buy It Now | Add to watch list

Infliximab : Pharmacology, Uses and Limitations
End Date: Wednesday Jun-5-2019 5:37:20 PDT
Buy It Now for only: $54.46
Buy It Now | Add to watch list

REMICADE magazine clippings Pharmaceutical ads from 2004 Infliximab
End Date: Tuesday May-28-2019 20:25:07 PDT
Buy It Now for only: $2.96
Buy It Now | Add to watch list


* Latest Rheumatology News

       *** News Filter: "Infliximab"



Clinical Relapse Common After Infliximab Withdrawal in Ankylosing Spondylitis  Rheumatology Advisor

Two-thirds of patients with ankylosing spondylitis who achieved clinical remission with infliximab demonstrated symptom flares and clinical relapse soon after ...

More than two infliximab escalations may be unwarranted in RA  medwireNews

medwireNews: The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis (RA) may be limited to the initial two escalations, US study ...

More than half of patients in AS remission relapse after ceasing infliximab  Healio

Approximately 58% of patients in clinical remission after taking infliximab for ankylosing spondylitis relapse within 12 months after discontinuing the treatment, ...

US should 'learn from Europe' regarding biosimilar policy, adoption  Healio

CLEVELAND — The United States continues to lag far behind Europe in terms of biosimilar availability, and officials here should take a lesson from their peers ...

ANSWER Study: More Patients With RA Discontinue Adalimumab and Infliximab Due to Remission  The Center for Biosimilars

Adalimumab and infliximab showed the highest discontinuation rate due to patient remission, followed by golimumab, in the study of patients with rheumatoid ...

How Does Anti-TNF Withdrawal Affect Ankylosing Spondylitis?  DocWire News

A study evaluated outcomes for patients with ankylosing spondylitis in clinical remission being treated with anti-tumor necrosis factor therapy infliximab.

Treatment Outcomes: Should PsA Patients Switch Their TNFi or Change to non-TNFi?  DocWire News

Psoriatic arthritis (PsA) patients being treated with a tumor necrosis factor inhibitor (TNFi) may have a reduced financial burden and better treatment.

Researchers Report a Successful Switch and Suggest That Patient Education Played a Role  The Center for Biosimilars

The switch included patients with rheumatoid arthritis and psoriatic arthritis who were treated at a single center in Amsterdam, the Netherlands.

Young investigator forum highlights research from fellows, junior faculty  Healio

DESTIN, Fla. — More than 100 fellows and junior faculty members flocked to the 2019 North American Young Rheumatology Investigator Forum, where they ...

Medicare spending on DMARDs 'increased dramatically' over 4 years  Healio

DESTIN, Fla. — The amount of Medicare spending for conventional DMARDs used to treat rheumatoid arthritis ballooned from $98 million in 2012 to $550 ...



RHEUMATOLOGY101.COM --- Rheumatology News, Rheumatology Information, Find a Rheumatologist by State, Rheumatology Resources, Lots More

Need to Find information on any subject? ASK THE RHEUMATOLOGY101 GURU and click the BIG GREEN Button above!

 * Contact us:  support@z101.com

Copyright 2008-2015  RHEUMATOLOGY101.COM